Journal
TRANSLATIONAL LUNG CANCER RESEARCH
Volume 8, Issue 1, Pages 107-115Publisher
AME PUBL CO
DOI: 10.21037/tlcr.2018.08.16
Keywords
Stereotactic body radiation therapy (SBRT); stereotactic ablative radiotherapy; immunotherapy; checkpoint inhibitor; lung cancer
Categories
Ask authors/readers for more resources
Stereotactic body radiation therapy (SBRT) offers excellent local control of early-stage non-small cell lung cancer (NSCLC), but there currently is a need for tolerable systemic therapy to address regional and distant disease progression. One potential option is immunotherapy, which in metastatic NSCLC has shown promise for sustained disease control in a subset of patients. There is also growing evidence for a clinical synergy between radiation and immunotherapy, with several ongoing trials studying the abscopal effect. This review summarizes the current data in the fast-changing field of immuno-radiation therapy, highlighting updates from recent clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available